Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Prioritizes Gene Therapy Production With AZ Facility Buy

Executive Summary

A US plant will become the largest of four state-of-the-art sites involved in manufacturing of Novartis unit Avexis' gene therapies headed by Zolgensma, which is widely expected to get the green light from the FDA in May.

Advertisement

Related Content

Deal Watch: Editas, BlueRock Ink Cross-Licensing Technology Collaboration
Price ‘Anchoring’? Zolgensma And The Art Of Managing Gene Therapy Sticker Shock
Novartis Pharma CEO Sees Zolgensma Supplanting Spinraza
Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisition

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel